| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1272 | |
| Phytochemical name or plant extracts | Amorphophalli rhizoma extract | |
| PMID | 30731183 | |
| Literature evidence | ETHNOPHARMACOLOGICAL RELEVANCE: Amorphophalli Rhizoma has been widely used as an adjuvant treatment for advanced or metastatic breast cancer, pancreatic cancer, hepatoma, and malignant lymphoma, but its molecular mechanism of action for treatment of metastatic triple-negative breast cancer (TNBC) is generally poorly understood. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Extract | |
| Source of phytochemicals or plant Extracts | Amorphophallus konjac Amorphophallus rivieri Amorphophallus sinensis | |
| Geographical availability | China South-Central | |
| Plant parts | Rhizome | |
| Other cancers | Breast cancer, Pancreatic cancer, Lymphoma, Stomach cancer | |
| Target gene or protein | KNL-1, OLFML2A, RTKN2 | |
| Gene or Protein evidence | Attenuation of KNL1, OLFML2A, RTKN2 and SGO1 gene expression by Amorphophalli Rhizoma significantly induced cell cycle arrest and suppressed cell proliferation and migration. | |
| Target pathways | Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway | |
| IC50 | 406 µg/ml against MDA-MB-231 458 µg/ml against MDA-MB-231BO | |
| Potency | NA | |
| Cell line/ mice model | MDA-MB-231, MDA-MB-231BO | |
| Additional information | The inhibitory effects of Amorphophalli Rhizoma in TNBC cells likely occur through regulation of the spindle checkpoint, chromosomal and centrosomal instability, and cell membrane stability. | |
| PubChem ID | NA | |
| Additional PMIDs | 34929308 28962890 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:84377-1 | |
| Safety | NA |